Personal genetics company 23andMe, which provides individuals personal DNA analysis and interpretation services, announced a $9 million addition to its Series C Financing round, increasing the sum raised in the round to a total of $31 million. The round was first announced in November 2010, and its closing involved two new participants including MPM Capital and the Johnson & Johnson Development Corporation.

“With this closing, MPM Capital joins Johnson & Johnson Development Corporation as new investors and MPM Capital Managing Director Ashley Ledbetter Dombkowski, PhD is joining 23andMe’s Board of Directors.

“By combining state-of-the-art genotyping technology with sophisticated information technology tools, 23andMe is helping to usher in the age of personalized medicine in a way that can truly empower individuals while in parallel fueling ground breaking research,” said Dombkowski.

Dr. Dombkowski was recently named one of the Most Influential Women of 2010 by the San Jose/Silicon Valley Business Journal, and brings 15 years of biotech, medical device and pharmaceutical investment managing experience to the company. The genetics company, which offers an insight on one’s physical traits and risk factors in exchange of a saliva sample, $199 and a $5/month subscription.